TGA and ARTG readiness for medical devices in Australia

Regulator: Therapeutic Goods Administration (TGA). Market access is via inclusion in the Australian Register of Therapeutic Goods (ARTG) under the Therapeutic Goods Act 1989 (Cth) and the Therapeutic Goods (Medical Devices) Regulations 2002. The core technical obligations are the Essential Principles (Schedule 1) and the Conformity Assessment Procedures (Schedule 3). Applications and post‑market interactions are managed in TGA Business Services (TBS). Australia’s framework aligns with IMDRF and recognizes evidence from comparable overseas regulators. Recent significant device reforms include: 2021 amendments clarifying regulation of software‑based medical devices and personalized medical devices; ongoing IVD alignment and audit expectations; and 2024–2026 rollout of Australia’s Unique Device Identification (UDI) system and database (AusUDID), with staged obligations starting from higher‑risk classes. Sponsors (locally established entities responsible for supply) must hold and maintain manufacturer evidence (e.g., CE/MDSAP) and ensure ongoing compliance with conditions of inclusion, the Essential Principles, and TGA post‑market directions. Record retention periods generally follow Schedule 3: at least 5 years (most devices) and 15 years for implantable devices.

General medical devices are classified per rules in the Regulations (aligned with IMDRF): Class I (low risk), Class Is (sterile), Class Im (with measuring function), Class IIa (low‑medium), Class IIb (medium‑high), Class III (high), and Active Implantable Medical Devices (AIMD). Classification is based on intended purpose, invasiveness, duration of contact, and whether the device is active/implantable. Examples: non‑sterile accessories may be Class I; sterilized single‑use surgical instruments often Class Is; infusion pumps Class IIb; orthopedic implants Class III; pacemakers AIMD. Software as a medical device (SaMD) is classified according to clinical risk of the intended purpose; patient‑management or diagnostic influence typically elevates to Class IIa/IIb, while treatment‑critical algorithms can be Class III. IVD medical devices follow a separate four‑tier framework (Class 1 to Class 4). Class 4 IVDs (e.g., HIV blood screening) and many self‑testing IVDs are highest risk; Class 2 covers moderate public health risk; Class 1 are low risk (e.g., simple specimen receptacles). Misclassification is a common cause of delay; always validate rule application against Australian definitions and TGA SaMD/IVD guidance.

Premarket steps: 1) Determine classification and Essential Principles applicability (Schedule 1). 2) Select the appropriate Conformity Assessment Procedure (Schedule 3) and compile a technical file (STED/TD): EP checklist and evidence, design dossier (for Class III/AIMD), risk management per ISO 14971, clinical evaluation (or performance evaluation for IVDs), software files per IEC 62304 (if applicable), manufacturing/sterility validations, labels/IFU/PIL, and PMS plan. 3) Appoint an Australian Sponsor (local entity) to lodge Manufacturer’s Evidence (ME) in TBS. TGA accepts ME from Comparable Overseas Regulators (COR), including EU MDR/IVDR Notified Body certificates, US FDA PMA/De Novo/510(k) (as supporting evidence), Health Canada licenses, PMDA/MHLW approvals, and UK certifications, plus MDSAP audit reports for QMS. 4) Submit the ARTG inclusion application. TGA conducts automatic processing for Class I (non‑sterile, non‑measuring) and targeted application audits for higher classes: Level 1 (focused) or Level 2 (comprehensive). Mandatory audits generally apply for Class IIb implantables and Class III/AIMD, and for higher‑risk IVDs. Where required (e.g., certain Class III/AIMD or if overseas evidence is not acceptable/sufficient), TGA performs a Conformity Assessment (its own QMS/design examination). Timelines vary: Class I self‑certification is near‑immediate; applications supported by COR evidence and no audit often conclude in 1–3 months; Level 1 audits may take ~2–4 months; Level 2 or TGA Conformity Assessment can extend to 6–12+ months, excluding sponsor clock‑stops. All devices, once included, receive an ARTG entry that is publicly searchable.

Australia requires an appropriate QMS for the chosen Conformity Assessment Procedure; ISO 13485:2016 conformity is the expected baseline. TGA is a participating regulator in MDSAP and accepts MDSAP audit reports as QMS evidence, significantly reducing TGA audit burden for most devices. QMS scope must cover design/development, purchasing and supplier control, production, servicing, UDI/traceability processes, complaint handling, vigilance, and change control mapped to Australian Essential Principles and conditions of inclusion. For SaMD, IEC 62304 lifecycle controls, configuration management, cybersecurity risk treatment, and clinical evaluation evidence are expected. For sterile devices, process validations and environmental controls must be documented. Record retention: maintain technical documentation and QMS records at least 5 years (most devices) and 15 years for implantables, accessible to the Australian Sponsor. If seeking a TGA Conformity Assessment certificate, expect a document review and, where applicable, on‑site audits against ISO 13485 plus Australian regulatory specificities.

Australia’s UDI system (AusUDID) is rolling out in stages during 2024–2026, starting with higher‑risk classes. UDI follows IMDRF principles: device identifiers (DI) and production identifiers (PI), with accepted issuing agencies (e.g., GS1, HIBCC, ICCBBA). Sponsors must submit UDI master data to AusUDID and ensure UDI appears on device labels and relevant packaging; direct part marking applies to reusable devices as required after the transition deadlines. Labelling must meet Essential Principle 13: English language, intended purpose, manufacturer’s name and address, batch/serial, storage/handling, warnings/contraindications, and for sterile/measuring devices appropriate statements and accuracy. eIFU is permissible under TGA conditions for eligible devices. Australia mandates Patient Information Leaflets (PIL) and Patient Implant Cards (PIC) for implantable (and many Class III) devices: content must include intended purpose, clinical benefits, known risks, precautions, expected lifetime, materials, MRI compatibility, and instructions for patients; PICs must enable traceability (model, serial/lot, and UDI where available). IVD labels must include reagents/components, sample types, performance claims, and testing conditions.

Once included in the ARTG, devices are subject to TGA post‑market monitoring, targeted reviews, and possible conditions of inclusion. Sponsors must establish complaint handling, issue evaluation, corrective actions, and trend analysis. Adverse events are reported via the Medical Device Incident Reporting (MDIR) system within strict timelines: 2 calendar days for a serious public health threat; 10 days for events causing death or serious deterioration in health; 30 days for other reportable events. Sponsors coordinate Field Safety Corrective Actions (recalls, corrections) under the Uniform Recall Procedure for Therapeutic Goods (URPTG) and must notify users and TGA as required. Sponsors must maintain distribution/implant records to enable traceability and support UDI‑based tracking as it becomes mandatory. For IVDs, ongoing performance evaluation, lot trending, and stability monitoring are expected; significant performance issues trigger reportable events. TGA may request periodic reports for certain higher‑risk or novel devices. Advertising and claims must remain consistent with the intended purpose cleared for Australia.

Days 0–30: Appoint/confirm an Australian Sponsor and execute quality/technical data access agreements. Finalize intended purpose statements and classification (general MD or IVD). Perform an Essential Principles gap assessment; align clinical/performance evidence and risk files (ISO 14971). For SaMD, fix IEC 62304 documentation scope and cybersecurity risk controls. Map labelling, UDI plan, and implant patient‑materials needs. Days 31–60: Compile Manufacturer’s Evidence (e.g., EU MDR/IVDR certificate, FDA documentation, Health Canada license, MDSAP). Build or update the technical file: EP checklist, DHF, verification/validation, sterility, labeling/IFU/PIL/PIC, PMS plan. Validate QMS/production software (CSV/CSA). Days 61–90: Sponsor lodges ME in TBS, then files ARTG application(s). Pre‑stage responses to common audit queries (clinical equivalence, software safety classification, biocompatibility, shelf life). Establish complaint/vigilance SOPs and URPTG recall roles. Days 91–180: Address TGA application audits (Level 1/2) promptly; finalize AusUDID data for devices in scope of the current UDI phase; execute training on Australian labelling and patient materials; implement distribution traceability. If TGA Conformity Assessment is needed, expand the plan to 6–12+ months and schedule pre‑audit readiness checks and mock interviews.